Execution of the Medium-Term Management Plan 2027 and the 2030 Vision
First written in FY2025. 3 of 4 entries say "Advanced", first in FY2026-H1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In addition to promoting cost reductions, the Company carried out organisational restructuring at headquarters and within its business divisions. It worked to improve working capital by improving accounts receivable collection periods and accounts payable payment periods and reducing inventories, while seeking to improve investment efficiency by prioritising investments.」
As part of the structural reforms under Medium-Term Management Plan 2027, the Company implemented cost reductions, restructured headquarters and business divisions, improved working capital and prioritised investments. It is also advancing the development of methods for calculating and managing ROIC. - 2026-06-03AdvancedGeneral Meetings of Shareholders
「During the current fiscal year, we have been steadily implementing various measures under the 3 priority initiatives set out in the Medium-Term Management Plan 2027, and overall progress has been solid and in line with the plan.」
Regarding Medium-Term Management Plan 2027, the company described specific progress in structural reforms, stronger portfolio management, and a focus on the diagnostics and life sciences fields, citing the agreement to transfer the Eversense distribution business, the launch of LiCellGrow sales, and domestic approval and launch of E1000 Dx as implemented initiatives. - FY2026-H1AdvancedAnnual report
「Last autumn, the Company announced Medium-Term Management Plan 2027 and is pursuing improved profitability and more efficient business operations through structural reform aimed at strengthening the earnings base and improving investment efficiency, stronger portfolio management, and clearer positioning of the portfolio based on the growth potential and ROIC of each business to enhance investment efficiency.」
Regarding stronger portfolio management under Medium-Term Management Plan 2027, the Company proceeded to clarify portfolio positioning based on growth potential and ROIC, reaching the concrete execution stage with a basic agreement to transfer the Eversense sales business. - FY2025First statedAnnual report
「Under Phase 1 of Medium-Term Management Plan 2027, the Company will implement 3 priority initiatives: structural reform to strengthen the earnings base, stronger portfolio management, and a focus on the Diagnostics and Life Sciences fields.」
In November 2024, the Company formulated Medium-Term Management Plan 2027, dividing the period through 2030 into Phase 1, focused on building the foundation, and Phase 2, focused on sustainable growth centred on Diagnostics and Life Sciences, and established 3 priority initiatives.